What dose of sulbutiamine do labels and trials give?

Tablet strength and labelled dose
ProductStrengthLabelled doseLength
Arcalion (France)200 mg coated tablet12 to 3 tablets a day, adults only1Limited to four weeks1

Tablet strength and labelled dose

The table is set at the top of the page

Sulbutiamine has no US label: a DailyMed search found none, and the FDA wrote in an April 2025 warning letter that it is not a dietary ingredient.5 The French label gives the route as oral and says to swallow the tablets whole with a large glass of water, spread over the morning and midday meals.1 It says safety and efficacy in children and adolescents have not been established and that it must not be used in them.1 The label's indication is certain states of physical or mental inhibition with reduced activity and apathy.1

The label limits treatment to four weeks, and the leaflet says to see a doctor if there is no improvement, or the person feels worse, after four weeks.16 Neither source states a cycle or break schedule. The highest daily human dose in the sourced material is 600 mg, given in the Tiev trial and equal to the label's upper figure of three 200 mg tablets.21

Doses in human trials

TrialDose and schedulePeopleLength
Tiev, 1999, double-blind, placebo-controlled2400 mg daily, 600 mg daily or placebo326 general-practice patients with chronic postinfectious fatigue (106 on 400 mg, 111 on 600 mg, 109 on placebo)28 days
Sevim, 20173400 mg orally once daily, advisedTwenty-six patients with multiple sclerosis and fatigue (18 women, 8 men)Two months
Ahmed Mahmoud, 2026, randomised4100 mg/day alone or with imipramine 25 mg/day, against imipramine 25 mg/day alone4; the registry entry gives 100 mg daily by mouth for 1 month7450 children aged 6 to 18 with nocturnal enuresis, in three equal groupsFollowed for six months4
Kiew, 2002, open randomised controlled8Sulbutiamine (Arcalion) or no treatmentThirty people with type 2 diabetes and diabetic polyneuropathy (15 per group)6 weeks

The Sevim study ran two months and the Kiew trial 6 weeks, both longer than the label's four weeks.381 The 100 mg/day dose was given to children, whom the French label excludes.41

Powder, mixing and converting to tablets

A search of the French label, the trial registry and PubMed text found no instruction for mixing sulbutiamine powder with water. No concentration per mL exists for any labelled form, only the 200 mg tablet, so a dose converts by tablets of 200 mg each.1 A U-100 syringe does not apply to an oral tablet; units and syringe maths are covered in units and dosing.

Storage

On the French label, blister-packed tablets are kept at no more than 25°C and tablets in a pill bottle at no more than 30°C.1 The shelf life is three years for blister packs and two years for bottles.1 The sources give no storage time for sulbutiamine mixed or dissolved; a laboratory stress-degradation paper says its two ester groups make it highly susceptible to hydrolysis, yet found it stable under neutral hydrolysis and dry heat.9

Frequently asked questions

Is sulbutiamine authorised anywhere?

The French public medicines database shows Arcalion (Servier) authorised on 28/08/1996.10

What warnings does the label state?

The label's contraindication is hypersensitivity to the active substance or any excipient, and the tablets contain lactose, glucose and sucrose.1 It lists agitation, headache, tremor, nausea, vomiting, rash and malaise as uncommon adverse effects.1

Are there registered sulbutiamine trials?

The only sulbutiamine study found in the ClinicalTrials.gov registry is the Sohag University enuresis trial (NCT06497647), with an estimated enrolment of 450 and an overall status of unknown.7

References

  1. ANSM (text reproduced on pharma-gdd.com). Résumé des Caractéristiques du Produit. pharma-gdd.com
  2. PubMed. [Treatment of chronic postinfectious fatigue: randomized double-blind study of two doses of sulbutiamine (400-600 mg/day) versus placebo]. 1999. pubmed.ncbi.nlm.nih.gov
  3. PubMed. Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis. 2017. pubmed.ncbi.nlm.nih.gov
  4. PubMed. Comparative evaluation of sulbutiamine and imipramine in the treatment of primary nocturnal enuresis: A randomized controlled clinical study. 2026. pubmed.ncbi.nlm.nih.gov
  5. FDA. Gluten Free Remedies LLC - 687832 - 04/15/2025. fda.gov
  6. ANSM (notice reproduced on pharma-gdd.com). Notice patient. pharma-gdd.com
  7. ClinicalTrials.gov. NCT06497647: New Treatment for Nocturnal Enuresis in Children. 2024. clinicaltrials.gov
  8. PMC. Effects of Sulbutiamine on Diabetic Polyneuropathy: An Open Randomised Controlled Study in Type 2 Diabetics. pmc.ncbi.nlm.nih.gov
  9. PMC. Stability-Indicating HPTLC Method for Studying Stress Degradation Behavior of Sulbutiamine HCl. pmc.ncbi.nlm.nih.gov
  10. Base de données publique des médicaments. Base de Données Publique des Médicaments. base-donnees-publique.medicaments.gouv.fr